Roos J Jutten, Emily H Ho, Tatiana Karpouzian-Rogers, Carol van Hulle, Cynthia Carlsson, Hiroko H Dodge, Cindy J Nowinski, Richard Gershon, Sandra Weintraub, Dorene M Rentz
{"title":"Computerized cognitive testing to capture cognitive decline in Alzheimer's disease: Longitudinal findings from the ARMADA study.","authors":"Roos J Jutten, Emily H Ho, Tatiana Karpouzian-Rogers, Carol van Hulle, Cynthia Carlsson, Hiroko H Dodge, Cindy J Nowinski, Richard Gershon, Sandra Weintraub, Dorene M Rentz","doi":"10.1002/dad2.70046","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Timely detection and tracking of Alzheimer's disease (AD) -related cognitive decline has become a public health priority. We investigated whether the NIH Toolbox for Assessment of Neurological and Behavioral Function-Cognition Battery (NIHTB-CB) detects AD-related cognitive decline.</p><p><strong>Methods: </strong><i>N</i> = 171 participants (age 76.5 ± 8; 53% female, 34% Aβ-positive) from the ARMADA study completed the NIHTB-CB at baseline, 12 months, and 24 months. Linear mixed-effect models correcting for demographics were used to examine cross-sectional and longitudinal NIHTB-CB scores in individuals across the clinical AD spectrum.</p><p><strong>Results: </strong>Compared to Aβ-negative healthy controls, Aβ-positive individuals with amnestic MCI or mild AD performed worse on all NIHTB-CB measures and showed an accelerated decline in processing speed, working memory, and auditory word comprehension tests.</p><p><strong>Discussion: </strong>These findings support the use of the NIHTB-CB in early AD, but also imply that the optimal NIHTB-CB composite score to detect change over time may differ across clinical stages of AD. Future directions include replication of these findings in larger and more demographically diverse samples.</p><p><strong>Highlights: </strong>We examined NIH Toolbox-Cognition Battery scores across the clinical AD spectrum.All NIH Toolbox tests detected cross-sectional cognitive impairment in MCI-to-mild AD.Three NIH Toolbox tests captured further decline over time in MCI-to-mild AD.The NIH Toolbox can facilitate timely detection of AD-related cognitive decline.</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"17 1","pages":"e70046"},"PeriodicalIF":4.0000,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730193/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/dad2.70046","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Timely detection and tracking of Alzheimer's disease (AD) -related cognitive decline has become a public health priority. We investigated whether the NIH Toolbox for Assessment of Neurological and Behavioral Function-Cognition Battery (NIHTB-CB) detects AD-related cognitive decline.
Methods: N = 171 participants (age 76.5 ± 8; 53% female, 34% Aβ-positive) from the ARMADA study completed the NIHTB-CB at baseline, 12 months, and 24 months. Linear mixed-effect models correcting for demographics were used to examine cross-sectional and longitudinal NIHTB-CB scores in individuals across the clinical AD spectrum.
Results: Compared to Aβ-negative healthy controls, Aβ-positive individuals with amnestic MCI or mild AD performed worse on all NIHTB-CB measures and showed an accelerated decline in processing speed, working memory, and auditory word comprehension tests.
Discussion: These findings support the use of the NIHTB-CB in early AD, but also imply that the optimal NIHTB-CB composite score to detect change over time may differ across clinical stages of AD. Future directions include replication of these findings in larger and more demographically diverse samples.
Highlights: We examined NIH Toolbox-Cognition Battery scores across the clinical AD spectrum.All NIH Toolbox tests detected cross-sectional cognitive impairment in MCI-to-mild AD.Three NIH Toolbox tests captured further decline over time in MCI-to-mild AD.The NIH Toolbox can facilitate timely detection of AD-related cognitive decline.
期刊介绍：
Alzheimer''s & Dementia: Diagnosis, Assessment & Disease Monitoring (DADM) is an open access, peer-reviewed, journal from the Alzheimer''s Association® that will publish new research that reports the discovery, development and validation of instruments, technologies, algorithms, and innovative processes. Papers will cover a range of topics interested in the early and accurate detection of individuals with memory complaints and/or among asymptomatic individuals at elevated risk for various forms of memory disorders. The expectation for published papers will be to translate fundamental knowledge about the neurobiology of the disease into practical reports that describe both the conceptual and methodological aspects of the submitted scientific inquiry. Published topics will explore the development of biomarkers, surrogate markers, and conceptual/methodological challenges. Publication priority will be given to papers that 1) describe putative surrogate markers that accurately track disease progression, 2) biomarkers that fulfill international regulatory requirements, 3) reports from large, well-characterized population-based cohorts that comprise the heterogeneity and diversity of asymptomatic individuals and 4) algorithmic development that considers multi-marker arrays (e.g., integrated-omics, genetics, biofluids, imaging, etc.) and advanced computational analytics and technologies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
